Dark Genome Target Discovery and Development Summit

Welcome to the Inaugural Dark Genome Target Discovery and Development Summit

The Dawn of the Dark Genome Has Arrived...

Significant technological advances in computational biology, next-gen sequencing, -omics platforms and AI have unlocked the transformative potential of drug discovery in the dark genome, resulting in investment and partnerships totalling over $1.5 billion in the past 6 months alone.

Speakers: Adam Cribbs, Co-Founder and Chief Technology Officer, Caeruleus Genomics, Chris Burge, Whitaker Professor of Biology, Massachusetts Institute of Technology, Dan Tardiff, Vice President, Head of Discovery, CAMP4 Therapeutics, David Bumcrot, Chief Scientific Officer, CAMP4 Therapeutics, Eric Halioua, President and Chief Executive Officer, PDC*line Pharma, Generoso Ianniciello, Chief Business Officer, Anima Biotech, Hong Liu, Vice President and Head of Computational Biology, NextRNA, J. Robert Coleman, Chief Executive Officer, HERVolution Therapeutics, Jens Hukelmann, Associate Director - Target Research, Immatics, Jens Kringelum, Vice President, AI and Innovation, Evaxion Biotech, Jonathan Kwok, Chief Executive Officer and Co-Founder, Infinitopes Precision Immunomics and Oxford University, Kim Long, Vice President, Biology and Translational Sciences, ROME Therapeutics, Liyang Diao, Senior Director, Data Science, ROME Therapeutics, Matthew Maurano, Assistant Professor, Institute for Systems Genetics and Department of Pathology, NYU Medical Lab, Michael Saitakis, Director - Immunotherapy, Mnemo Therapeutics, Peter Holst, Chief Scientific Officer, HERVolution Therapeutics, and more